Personal genomic testing for cancer risk: Results from the impact of personal genomics study

Stacy W. Gray, Sarah E. Gollust, Deanna Alexis Carere, Clara A. Chen, Angel Cronin, Sarah S. Kalia, Huma Q. Rana, Mack T. Ruffin Iv, Catharine Wang, J. Scott Roberts, Robert C. Green

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose Significant concerns exist regarding the potential for unwarranted behavior changes and the overuse of health care resources in response to direct-To-consumer personal genomic testing (PGT). However, little is known about customers' behaviors after PGT. Methods Longitudinal surveys were given to new customers of 23andMe (Mountain View, CA) and Pathway Genomics (San Diego, CA). Survey data were linked to individual-level PGT results through a secure data transfer process. Results Of the 1,042 customers who completed baseline and 6-month surveys (response rate, 71.2%), 762 had complete cancer-related data and were analyzed. Most customers reported that learning about their genetic risk of cancers was a motivation for testing (colorectal, 88%; prostate, 95%; breast, 94%). No customers tested positive for pathogenic mutations in highly penetrant cancer susceptibility genes. A minority of individuals received elevated single nucleotide polymorphism-based PGT cancer risk estimates (colorectal, 24%; prostate, 24%; breast, 12%). At 6 months, customers who received elevated PGT cancer risk estimates were not significantly more likely to change their diet, exercise, or advanced planning behaviors or engage in cancer screening, compared with individuals at average or reduced risk. Men who received elevated PGT prostate cancer risk estimates changed their vitamin and supplement use more than those at average or reduced risk (22% v 7.6%, respectively; adjusted odds ratio, 3.41; 95% CI, 1.44 to 8.18). Predictors of 6-month behavior include baseline behavior (exercise, vitamin or supplement use, and screening), worse health status (diet and vitamin or supplement use), and older age (advanced planning, screening). Conclusion Most adults receiving elevated direct-To-consumer PGT single nucleotide polymorphism-based cancer risk estimates did not significantly change their diet, exercise, advanced care planning, or cancer screening behaviors.

Original languageEnglish (US)
Pages (from-to)636-644
Number of pages9
JournalJournal of Clinical Oncology
Volume35
Issue number6
DOIs
StatePublished - Feb 20 2017

Fingerprint

Genomics
Neoplasms
Vitamins
Exercise
Diet
Early Detection of Cancer
Single Nucleotide Polymorphism
Prostate
Breast
Health Resources
Neoplasm Genes
Health Status
Longitudinal Studies
Motivation
Prostatic Neoplasms
Odds Ratio
Learning
Delivery of Health Care
Mutation

Cite this

Personal genomic testing for cancer risk : Results from the impact of personal genomics study. / Gray, Stacy W.; Gollust, Sarah E.; Carere, Deanna Alexis; Chen, Clara A.; Cronin, Angel; Kalia, Sarah S.; Rana, Huma Q.; Ruffin Iv, Mack T.; Wang, Catharine; Roberts, J. Scott; Green, Robert C.

In: Journal of Clinical Oncology, Vol. 35, No. 6, 20.02.2017, p. 636-644.

Research output: Contribution to journalArticle

Gray, SW, Gollust, SE, Carere, DA, Chen, CA, Cronin, A, Kalia, SS, Rana, HQ, Ruffin Iv, MT, Wang, C, Roberts, JS & Green, RC 2017, 'Personal genomic testing for cancer risk: Results from the impact of personal genomics study', Journal of Clinical Oncology, vol. 35, no. 6, pp. 636-644. https://doi.org/10.1200/JCO.2016.67.1503
Gray, Stacy W. ; Gollust, Sarah E. ; Carere, Deanna Alexis ; Chen, Clara A. ; Cronin, Angel ; Kalia, Sarah S. ; Rana, Huma Q. ; Ruffin Iv, Mack T. ; Wang, Catharine ; Roberts, J. Scott ; Green, Robert C. / Personal genomic testing for cancer risk : Results from the impact of personal genomics study. In: Journal of Clinical Oncology. 2017 ; Vol. 35, No. 6. pp. 636-644.
@article{a81c1e534730431db35c586efdb11281,
title = "Personal genomic testing for cancer risk: Results from the impact of personal genomics study",
abstract = "Purpose Significant concerns exist regarding the potential for unwarranted behavior changes and the overuse of health care resources in response to direct-To-consumer personal genomic testing (PGT). However, little is known about customers' behaviors after PGT. Methods Longitudinal surveys were given to new customers of 23andMe (Mountain View, CA) and Pathway Genomics (San Diego, CA). Survey data were linked to individual-level PGT results through a secure data transfer process. Results Of the 1,042 customers who completed baseline and 6-month surveys (response rate, 71.2{\%}), 762 had complete cancer-related data and were analyzed. Most customers reported that learning about their genetic risk of cancers was a motivation for testing (colorectal, 88{\%}; prostate, 95{\%}; breast, 94{\%}). No customers tested positive for pathogenic mutations in highly penetrant cancer susceptibility genes. A minority of individuals received elevated single nucleotide polymorphism-based PGT cancer risk estimates (colorectal, 24{\%}; prostate, 24{\%}; breast, 12{\%}). At 6 months, customers who received elevated PGT cancer risk estimates were not significantly more likely to change their diet, exercise, or advanced planning behaviors or engage in cancer screening, compared with individuals at average or reduced risk. Men who received elevated PGT prostate cancer risk estimates changed their vitamin and supplement use more than those at average or reduced risk (22{\%} v 7.6{\%}, respectively; adjusted odds ratio, 3.41; 95{\%} CI, 1.44 to 8.18). Predictors of 6-month behavior include baseline behavior (exercise, vitamin or supplement use, and screening), worse health status (diet and vitamin or supplement use), and older age (advanced planning, screening). Conclusion Most adults receiving elevated direct-To-consumer PGT single nucleotide polymorphism-based cancer risk estimates did not significantly change their diet, exercise, advanced care planning, or cancer screening behaviors.",
author = "Gray, {Stacy W.} and Gollust, {Sarah E.} and Carere, {Deanna Alexis} and Chen, {Clara A.} and Angel Cronin and Kalia, {Sarah S.} and Rana, {Huma Q.} and {Ruffin Iv}, {Mack T.} and Catharine Wang and Roberts, {J. Scott} and Green, {Robert C.}",
year = "2017",
month = "2",
day = "20",
doi = "10.1200/JCO.2016.67.1503",
language = "English (US)",
volume = "35",
pages = "636--644",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Personal genomic testing for cancer risk

T2 - Results from the impact of personal genomics study

AU - Gray, Stacy W.

AU - Gollust, Sarah E.

AU - Carere, Deanna Alexis

AU - Chen, Clara A.

AU - Cronin, Angel

AU - Kalia, Sarah S.

AU - Rana, Huma Q.

AU - Ruffin Iv, Mack T.

AU - Wang, Catharine

AU - Roberts, J. Scott

AU - Green, Robert C.

PY - 2017/2/20

Y1 - 2017/2/20

N2 - Purpose Significant concerns exist regarding the potential for unwarranted behavior changes and the overuse of health care resources in response to direct-To-consumer personal genomic testing (PGT). However, little is known about customers' behaviors after PGT. Methods Longitudinal surveys were given to new customers of 23andMe (Mountain View, CA) and Pathway Genomics (San Diego, CA). Survey data were linked to individual-level PGT results through a secure data transfer process. Results Of the 1,042 customers who completed baseline and 6-month surveys (response rate, 71.2%), 762 had complete cancer-related data and were analyzed. Most customers reported that learning about their genetic risk of cancers was a motivation for testing (colorectal, 88%; prostate, 95%; breast, 94%). No customers tested positive for pathogenic mutations in highly penetrant cancer susceptibility genes. A minority of individuals received elevated single nucleotide polymorphism-based PGT cancer risk estimates (colorectal, 24%; prostate, 24%; breast, 12%). At 6 months, customers who received elevated PGT cancer risk estimates were not significantly more likely to change their diet, exercise, or advanced planning behaviors or engage in cancer screening, compared with individuals at average or reduced risk. Men who received elevated PGT prostate cancer risk estimates changed their vitamin and supplement use more than those at average or reduced risk (22% v 7.6%, respectively; adjusted odds ratio, 3.41; 95% CI, 1.44 to 8.18). Predictors of 6-month behavior include baseline behavior (exercise, vitamin or supplement use, and screening), worse health status (diet and vitamin or supplement use), and older age (advanced planning, screening). Conclusion Most adults receiving elevated direct-To-consumer PGT single nucleotide polymorphism-based cancer risk estimates did not significantly change their diet, exercise, advanced care planning, or cancer screening behaviors.

AB - Purpose Significant concerns exist regarding the potential for unwarranted behavior changes and the overuse of health care resources in response to direct-To-consumer personal genomic testing (PGT). However, little is known about customers' behaviors after PGT. Methods Longitudinal surveys were given to new customers of 23andMe (Mountain View, CA) and Pathway Genomics (San Diego, CA). Survey data were linked to individual-level PGT results through a secure data transfer process. Results Of the 1,042 customers who completed baseline and 6-month surveys (response rate, 71.2%), 762 had complete cancer-related data and were analyzed. Most customers reported that learning about their genetic risk of cancers was a motivation for testing (colorectal, 88%; prostate, 95%; breast, 94%). No customers tested positive for pathogenic mutations in highly penetrant cancer susceptibility genes. A minority of individuals received elevated single nucleotide polymorphism-based PGT cancer risk estimates (colorectal, 24%; prostate, 24%; breast, 12%). At 6 months, customers who received elevated PGT cancer risk estimates were not significantly more likely to change their diet, exercise, or advanced planning behaviors or engage in cancer screening, compared with individuals at average or reduced risk. Men who received elevated PGT prostate cancer risk estimates changed their vitamin and supplement use more than those at average or reduced risk (22% v 7.6%, respectively; adjusted odds ratio, 3.41; 95% CI, 1.44 to 8.18). Predictors of 6-month behavior include baseline behavior (exercise, vitamin or supplement use, and screening), worse health status (diet and vitamin or supplement use), and older age (advanced planning, screening). Conclusion Most adults receiving elevated direct-To-consumer PGT single nucleotide polymorphism-based cancer risk estimates did not significantly change their diet, exercise, advanced care planning, or cancer screening behaviors.

UR - http://www.scopus.com/inward/record.url?scp=85013361160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013361160&partnerID=8YFLogxK

U2 - 10.1200/JCO.2016.67.1503

DO - 10.1200/JCO.2016.67.1503

M3 - Article

C2 - 27937091

AN - SCOPUS:85013361160

VL - 35

SP - 636

EP - 644

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -